Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice.

[1]  F. Hsiao,et al.  Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database , 2016, Osteoporosis International.

[2]  P. Vestergaard,et al.  Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study , 2015, Archives of Osteoporosis.

[3]  K. Kostev,et al.  Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider , 2014, Osteoporosis International.

[4]  R. Burge,et al.  Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study , 2013, Journal of osteoporosis.

[5]  P. Hadji,et al.  Adherence and persistence in patients with severe osteoporosis treated with teriparatide , 2010, Current medical research and opinion.

[6]  J. Adachi,et al.  Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. , 2007, Clinical therapeutics.

[7]  J. Cramer,et al.  Non-compliance: the Achilles' heel of anti-fracture efficacy , 2007, Osteoporosis International.

[8]  Jacques P. Brown,et al.  Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database , 2003, Osteoporosis International.